Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications
Normalization of CEA, CA15-3, and CA27-29 Tumor Markers Following Single Lung Transplant in a Patient With a History of Early-Stage Breast Cancer and Idiopathic Pulmonary Fibrosis: A Case Report.
Journal: Cancer reports (Hoboken, N.J.)
Published: October 07, 2024
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 15, 2023
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 07, 2023
Multiple receptor conversions during the course of metastatic breast cancer therapy: a case report and review of the literature.
Journal: Journal of medical case reports
Published: March 31, 2022
Advances in Therapeutic Approaches for Triple-Negative Breast Cancer.
Journal: Clinical breast cancer
Published: July 12, 2020
Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG).
Journal: Clinical breast cancer
Published: August 22, 2019
A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast Cancer.
Journal: Clinical breast cancer
Published: March 07, 2019
Vinorelbine plus Capecitabine (Vinocap): a retrospective analysis in heavily pretreated HER2 negative metastatic breast cancer patients.
Journal: Breast cancer research and treatment
Published: March 05, 2019
Addressing physician barriers to administering cyclin-dependent kinases 4 and 6 inhibitors in first-line treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
Journal: Cancer management and research
Published: January 19, 2019
Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG).
Journal: Breast cancer research and treatment
Published: April 03, 2018
When Can a Salvage Therapy (T-DM1) Take the Lead?
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 20, 2016
A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors.
Journal: Breast cancer research and treatment
Published: March 03, 2016
Last Updated: 09/26/2026